Sigyn Therapeutics (SIGY) Net Cash Flow (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Net Cash Flow of $85112.0 for Q3 2025, up 784.4% sequentially from -$12436.0 in Q2 2025, and down 23.42% YoY from $111144.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Net Cash Flow (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Net Cash Flow for 10 years, with the latest figure at $85112.0 in Q3 2025.
- Quarterly Net Cash Flow fell 23.42% year-over-year to $85112.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$79217.0 (down 179.06% YoY) and the FY2024 annual result came in at $454.0, down 86.38% from the prior year.
- Net Cash Flow rose to $85112.0 in Q3 2025 per SIGY's latest filing, from -$12436.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $1.1 million in Q2 2021 and troughed at -$557021.0 in Q3 2021.
- A 5-year average of $106.74 and a median of -$12436.0 in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 3122.25% in 2021, down 311.37% in 2021.
- Over 5 years, Net Cash Flow stood at -$162020.0 in 2021, then soared by 87.8% to -$19767.0 in 2022, then sank by 167.59% to -$52894.0 in 2023, then slumped by 188.58% to -$152644.0 in 2024, then jumped by 155.76% to $85112.0 in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $85112.0, -$12436.0, and $751.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 85,112.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 85,112.00 |
| Sep 30, 2025 | 85,112.00 |
| Jun 30, 2025 | -12,436.00 |
| Jun 30, 2025 | -12,436.00 |
| Mar 31, 2025 | 751.00 |
| Mar 31, 2025 | 751.00 |
| Dec 31, 2024 | -152,644.00 |
| Dec 31, 2024 | -152,644.00 |
| Sep 30, 2024 | 111,144.00 |
| Sep 30, 2024 | 111,144.00 |
| Jun 30, 2024 | 20,806.00 |
| Jun 30, 2024 | 20,806.00 |
| Mar 31, 2024 | 21,148.00 |
| Mar 31, 2024 | 21,148.00 |
| Dec 31, 2023 | -52,894.00 |
| Dec 31, 2023 | -52,894.00 |
| Sep 30, 2023 | 40,951.00 |
| Sep 30, 2023 | 40,951.00 |
| Jun 30, 2023 | -298,694.00 |
| Jun 30, 2023 | -298,694.00 |